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Abstract: Background: Choline is essential for the synthesis of liver phosphatidylcholine (PC),
parenchymal maintenance, bile formation, and lipoprotein assembly to secrete triglycerides.
In choline deficiency, the liver accretes choline/PC at the expense of lung tissue, thereby impairing
pulmonary PC homoeostasis. In cystic fibrosis (CF), exocrine pancreas insufficiency results in
impaired cleavage of bile PC and subsequent fecal choline loss. In these patients, the plasma
choline concentration is low and correlates with lung function. We therefore investigated the effect
of choline supplementation on plasma choline/PC concentration and metabolism, lung function,
and liver fat. Methods: 10 adult male CF patients were recruited (11/2014–1/2016), and orally
supplemented with 3 × 1 g choline chloride for 84 (84–91) days. Pre-/post-supplementation,
patients were spiked with 3.6 mg/kg [methyl-D9]choline chloride to assess choline/PC metabolism.
Mass spectrometry, spirometry, and hepatic nuclear resonance spectrometry served for analysis.
Results: Supplementation increased plasma choline from 4.8 (4.1–6.2) µmol/L to 10.5 (8.5–15.5)
µmol/L at d84 (p < 0.01). Whereas plasma PC concentration remained unchanged, D9-labeled PC was
decreased (12.2 [10.5–18.3] µmol/L vs. 17.7 [15.5–22.4] µmol/L, p < 0.01), indicating D9-tracer dilution
due to higher choline pools. Supplementation increased Forced Expiratory Volume in 1 second
percent of predicted (ppFEV1) from 70.0 (50.9–74.8)% to 78.3 (60.1–83.9)% (p < 0.05), and decreased
liver fat from 1.58 (0.37–8.82)% to 0.84 (0.56–1.17)% (p < 0.01). Plasma choline returned to baseline
concentration within 60 h. Conclusions: Choline supplementation normalized plasma choline
concentration and increased choline-containing PC precursor pools in adult CF patients. Improved
lung function and decreased liver fat suggest that in CF correcting choline deficiency is clinically
important. Choline supplementation of CF patients should be further investigated in randomized,
placebo-controlled trials.
Keywords: cystic fibrosis; choline deficiency; choline supplementation; lung function; liver; steatosis;
magnetic resonance spectroscopy; stable isotope labeling
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1. Introduction
Cystic fibrosis (CF) is a recessive autosomal disease, caused by mutations of the Cystic Fibrosis
Transmembrane Conductance Regulator (CFTR) gene. The CFTR protein is expressed in airways,
pancreatic and bile ducts, and other organs. Dysfunctional chloride and hydrogen carbonate transport
in the lungs results in sticky airway secretions, with impaired mucociliary clearance, microbial
colonization, inflammation, tissue degradation, and decline in lung function. Such a decline is linked
to increased concentrations of pro-apoptotic ceramides, triggered by cleavage of the choline-containing
phospholipid sphingomyelin (SPM) [1,2]. Ceramide removal via its conversion to SPM by SPM
synthase requires PC/choline as a substrate, which may be impaired in the well-described choline
deficiency of CF patients [3,4]. Moreover, exocrine pancreas insufficiency and bile duct dysfunction
cause maldigestion and CF-related liver disease (CFRLD), a result of alterations from hepatosteatosis
to biliary cirrhosis, in these patients [5–9]. Pancreatic enzyme substitution, improved nutrition, and
antibiotic treatment, have increased the median life expectancy of these patients to ~38–49 years [10,11].
Nevertheless, pulmonary and hepatic failure are the most frequent causes of death, and chronic choline
deficiency may contribute to clinical symptoms and impairment [4,12,13].
Choline is essential to all organs, including the lungs and liver as central organs of choline
trafficking and homeostasis, mainly in the form of phosphatidylcholine (PC) and SPM. Additionally,
choline is oxidized to betaine, an important methyl donor, e.g., for hepatic creatine synthesis [14].
Because endogenous PC and choline synthesis via hepatic phosphatidylethanolamine methylation is
not sufficient for human requirements, choline is an essential nutrient. The higher choline requirement
in CF is based on increased fecal loss, because the high amount of PC secreted into the duodenum via
bile requires a functioning enterohepatic cycle of this component [15–17]. However, exocrine pancreas
insufficiency in CF increases fecal PC loss and causes systemic choline deficiency. This is due to the
lack of pancreatic phospholipase A2 (pPLaseA2) activity, precluding an efficient enterohepatic cycle of
bile PC and, therefore, its choline moiety [4,12,18–20].
Choline is essential to pulmonary homeostasis, for the formation of PC of membranes, surfactant
and secretion into the circulation to feed lipoprotein trafficking. Similarly, choline is essential to the
liver, for PC of membranes, bile, and very low density lipoproteins (VLDL). A major fraction of the
choline PC newly synthesized by the liver contributes to systemic lipoprotein trafficking [21–24],
whereas in choline deficiency, a net PC/choline efflux from the lungs occurs to maintain liver
function [25]. Such a decrease in pulmonary choline availability may impair this organ’s PC
homeostasis. Consequently, recent data show that plasma choline and PC concentrations in CF
patients correlate with lung function, suggesting that choline deficiency may be clinically relevant
to these patients [13]. Spiking patients with [D9-methyl]choline in vivo shows rapid plasma choline
turnover, and results in a rapid increase and decrease of plasma PC, suggesting rapid turnover of PC,
too. Whereas mouse experiments showed that plasma PC kinetics reflects hepatic PC synthesis and
secretion, plasma peak levels of D9-PC in humans were at ~24–33 h, with decreased PC secretion in CF
patients [13,26,27].
We therefore supplemented, after power analysis, 10 adult male CF patients with 3 × 1 g/day
choline chloride for 84 (84–91) days, to correct for their choline deficiency, and measured the effects on
choline/PC homeostasis, lung function, and liver fat storage. Additionally, we spiked the patients with
[D9-methyl]choline chloride prior to and 12 h after the end of supplementation to assess the effects of
supplementation on choline and PC metabolism. As a primary outcome parameter, we investigated
the effect of supplementation on plasma D9-PC concentration, 33 h after [D9-methyl]choline chloride
administration. We further analyzed, as secondary parameters, the effects on lung function, liver and
muscle fat, muscle creatine and choline stores, and plasma choline and PC metabolism. This pilot
study is the first to integrate metabolic with clinical effects of choline supplementation in CF patients.
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2. Materials and Methods
2.1. Study Population
Ten male CF patients from 18 to 45 years (y) of age (median: 23 years) were enrolled for this
interventional trial. Patients were homozygous for Phe508del (N = 5) or compound heterozygous
(Phe508del/1717-1G->A [N = 1], Phe508del/Q552X [N = 1], Phe508del/3849+10kbC->T [N = 1] and
Phe508del/CFTRdele2,3(21kb) [N = 2]). CF was diagnosed at 2–23 months (N = 9) of age and at 10 y
in one case (Phe508del/1717-1G->A). In all patients exocrine pancreas insufficiency was diagnosed,
within 23 (N = 9) or at 118 months (N = 1, Phe508del/Phe508del) after CF diagnosis. All patients,
including one with Phe508del/3849+10kbC->T, required high-dose pancreatic enzyme substitution on
a daily basis. For inclusion parameters, primary and secondary end points, and anthropometric data,
see Appendix A, Tables A1 and A2. The trial was conducted in the Cystic Fibrosis Outpatient Clinic of
the Tübingen University Children’s Hospital, Germany. The protocol was approved by the Institutional
Review Board, and registered at ClinicalTrials.gov (Identifier: NCT 03312140). Data collection and
management was performed by the Center for Pediatric Clinical Studies (CPCS), University Children’s
Hospital, Tübingen. Screening was from 11/2014 to 1/2016. One hundred forty-five patients were
assessed for eligibility, and 10 of them were enrolled (see Appendix A, Figure A1).
2.2. Intervention
Patients were included after written consent following visit 1 (V1). Based on previous data on
choline supplementation in pediatric CF patients with 2 g/day (d) choline [28], an adequate intake
of 550 mg in healthy adult males and an upper tolerable limit of 3500 mg choline per day for adult
males [16], we supplemented the patients with 3 g/day choline chloride (=2.2 g/day choline). Patients
were instructed to draw, three times per day, 4 mL out of a 14-mL bottle with 250 mg/mL choline
chloride in sterile water (provided by the local university pharmacy), using a disposable 5-mL syringe,
to dissolve it with juice, and to drink the fluid together with their regular meals. Compliance was
controlled by telephone visits and by controlling for used and unused bottles at the intermediate visit
(V5) (49 (45–51) d) and at the end of supplementation (V6) (84(84–91) d).
2.3. Outcome and Safety Parameters
The primary outcome variable was the effect of choline supplementation after the end
of supplementation (V6–V8) on [D9-methyl]choline-labeled plasma phosphatidylcholine (D9-PC)
concentration, 33 h after [D9-methyl]choline administration. Predefined secondary outcome variables
were lung function and liver fat, together with the concentrations and kinetics of (D9-)choline,
water-soluble (D9-)choline metabolites, (D9-)PC and (D9-)PC subgroups in plasma to assess synthesis
and turnover (Appendix A, Table A2).
2.4. Sample Size Calculation
Based on the differences between the D9-PC concentration 33 h after intravenous
[D9-methyl]choline administration in a previous study, comparing CF patients with healthy
controls [13], an expected elevation of D9-PC from 1.468 to 2.217 µmol/L, standard deviation 0.74,
alpha of 0.05 and a power of 80%, a number of 12 patients was calculated. This included the possibility
of two drop-outs, which did not occur, so the study was terminated after 10 participants.
2.5. Investigation of Choline and Phosphatidylcholine (PC) Metabolism
To investigate the substitution effects on choline metabolism, patients were spiked orally with
3.6 mg/kg [D9-methyl]choline chloride (CDN Isotopes Inc., Pointe-Claire, Quebec, Canada), the same
dosage as previously used intravenously [13,26], prior to supplementation (V2) and 12–15 h after
the last choline chloride intake (V6). [D9-methyl]choline chloride was given as a single dosage, after
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overnight fasting, of a 50 mg/mL solution in sterile water (local university pharmacy) dissolved in 250
mL apple spritzer, together with a butter pretzel.
2.6. Blood Collection and Analytical Procedures
EDTA blood (2.7 mL) was taken by venous puncture 5 min before, and at 1 h, 2 h 3 h, 6 h, 9 h,
24 h, 33 h, and 48 h after [D9-methyl]choline ingestion at V2–4 and V6–8, and at V5 (intermediate
visit). Blood was immediately centrifuged at 1000× g for 10 min, and plasma and erythrocyte pellets
immediately frozen at −80 ◦C until analysis. For analysis, 100 µL plasma was spiked with internal
standards (D4-choline chloride, diarachinoyl-PC [PC20:0/20:0]), and extracted with chloroform and
methanol [29]. Analysis was performed with electrospray ionization tandem mass spectrometry
(ESI-MS/MS) as described before [21,26,27]. The chloroform phase was analyzed for unlabeled and
deuterated choline-containing PC and SPM. The methanol:water phase was analyzed for unlabeled and
deuterated choline, and its water-soluble metabolites betaine, dimethylglycine, and trimethylamine
oxide (TMAO).
2.7. Analysis of Choline, Choline Metabolites, and Phospholipids
Chloroform was of HPLC grade and from Baker (Deventer, The Netherlands). Methanol, water,
and ammonium hydroxide were of analytical grade and from Fluka Analytical/Sigma-Aldrich
(Munich, Germany). Phospholipid standards were from Avanti Polar Lipids (Alabaster, AL, USA) or
from Sigma-Aldrich (Munich, Germany), and purity checked by tandem mass spectrometry (see below).
[1,1,2,2-D4]choline chloride was purchased from Dr. Ehrenstorfer GmbH (Augsburg, Germany). All
other chemicals were of analytical grade and from various commercial sources.
Target analytes were quantified by ESI-MS/MS, using the specific reaction monitoring (SRM)
mode as described before [13,21]. Briefly, the equipment comprised a TSQ Quantum Discovery
MAX triple quadrupole mass spectrometer, a Finnigan Surveyor Autosampler Plus, and a Finnigan
Surveyor MS Pump Plus (Thermo Fisher Scientific, Dreieich, Germany). Choline, [D9-methyl]choline
(D9-choline), betaine, [D9-methyl]betaine (D9-betaine), dimethylglycine, trimethylamine oxide
(TMAO), and the internal standard (D4-choline) were analyzed using a ZORBAX HILIC Plus column
(2.1 × 100 mm inner diameter; 3.5 µm particle size; Agilent Technologies, Böblingen, Germany)
at 40 ◦C, a mobile phase of water:acetonitrile:formic acid (48:48:4, v/v) at 0.6 mL/min for 4 min,
and at positive ionization in the specific reaction monitoring (SRM) [30]. Deuterated and native
PC and SPM were separated on a Polaris Si-A (2 × 150 mm i.d.; 2 µm; Agilent Technologies),
with chloroform:methanol:300 mM ammonium acetate (60:38:2%, v/v) as the mobile phase, and
phosphocholine as a diagnostic fragment for PC and SPM quantification as described before [31,32].
2.8. Clinical Parameters
Lung function was determined using a model Jaeger Care Fusion Masterscreen body
plethysmograph (Vyaire Medical, Höchberg, Germany). Forced volume vital capacity (FVC), percent
of predicted forced expiratory volume in 1 s relative to FVC (ppFEV1), and forced expiratory flow at
25–75% of the pulmonary volume (FEF 25–75) were measured. A Magnetom Sonata, 1.5T (Siemens
Healthineers, Erlangen, Germany) was used for magnetic resonance spectroscopy, to assess the
concentrations of fat in liver and muscle tissue (anterior tibial and soleus muscle), and of muscle
creatine and choline. Creatine was analyzed because its hepatic synthesis requires activated methyl
groups that can originate from choline via betaine, methionine and S-adenosylmethionine [14,33].
2.9. Statistics
Data were controlled for normal distribution and provided as medians and interquartile ranges
if not indicated otherwise. Statistical analysis was performed using Instat®, version 3.10 (GraphPad,
La Jolla, CA, USA), using non-parametric testing. Pre-post comparisons of individual variables were
analyzed with Wilcoxon matched-pairs signed-ranks test, and multiple group comparisons (V2, V5,
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V6) with the Kruskal-Wallis Test. Kinetic data were analyzed with Spearman rank correlation. P-values
are reported and p < 0.05 was considered significant.
3. Results
3.1. Effects of Choline Supplementation on Plasma Choline and Its Water-Soluble Metabolites
All CF patients completed the study. Heart rate, blood pressure, hemoglobin oxygenation, weight,
and body mass index were in the normal range and did not change during the study. Triglycerides,
cholesterol, and routine parameters of liver/kidney function and inflammation did not change either
(Table A3).
Median fasting plasma choline prior to choline supplementation and 5 min prior to
[D9-methyl]choline labeling (V2) was 4.8(4.1–6.2) µmol/L. During supplementation at V5 (d49
(45–51)), 2–3 h after breakfast together with 1g choline chloride, plasma choline was 14.7 (11.8–16.2)
µmol/L (p < 0.01). At V6 (d84 (84–98)), 12–15 h after the last supplementation dose, plasma
choline was 10.5 (8.5–15.5) µmol/L (p < 0.01) (Figure 1A). Similarly, betaine, the major oxidation
product of choline, was increased after choline supplementation (Figure 1B). Dimethylglycine (DMG),
the demethylation product of betaine, was unchanged, whereas trimethylamine oxide (TMAO),
from bacterial choline catabolism, followed by hepatic oxidation, increased in response to choline
supplementation (Figure 1C,D).
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Figure 1. Effect of oral choline supplementation on the plasma concentration of choline (A) and its
water-soluble metabolites betaine, dimethylglycine (DMG) and trimethylamine oxide (TMAO) (B–D).
Bars represent values prior to (visit [V] 2), after 49 (45–51) days (V5) and after 84 (84–91) days (V6)
supplementation with 3 × 1 g choline chloride. Data are medians and interquartile ranges of CF
patients prior to (V2), and after 49 (45–51) days (V5) and 84 (84–91) days (V6) choline supplementation.
* p < 0.05; ** p < 0.01 vs. V2.
After the end of supplementation, choline, betaine and TMAO values returned to baseline
within 60 h (Figure 2A–C). According to the rapid choline turnover and absorption into tissues,
plasma [D9-methyl]choline concentration and D9-enrichment of choline were maximal 1 h after tracer
ingestion, but rapidly cleared from the circulation (Figure 3A,B). The concentration of D9-betaine
similarly increased (p < 0.001), indicating that choline supplementation stimulates its own degradation
(Figure 3C). However, D9-enrichment of betaine was decreased, indicating that increased synthesis of
D9-betaine after a single dose of [D9-methyl]choline was lower than the increase of unlabeled betaine
pools after 84 days of choline supplementation (Figure 3D). This is consistent with the slower turnover
of betaine compared to that of choline (Figure 2A,B, [13,26,27]).
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Figure 3. Kinetics of D9-Choline and D9-Betaine prior to (visit 2–4 [V2–4], white symbols) and from
12 h after the end of 84 (84–91 ays choline supplementation (V6–8, filled symbols). CF patients
(N = 10) were orally supplemented with 3 × 1 g choline chloride for 84 (84–91) d. Prior to (V2, open
symbols) and 12 h after the end of supplementation (V6, filled symbols) patients were spiked orally
with 3.6 mg/kg body weight [D9-methyl]choline chloride (D9-choline) and the kinetics of plasma
D9-choline (A) and D9-betaine (C) concentration and of D9-enrichment of choline (B) and betaine (D)
analyzed for 48 h (V2–4 and V6–8, respectively). Data are medians and interquartile ranges from
−5 min to 48 h after D9-choline ingestion. Abbreviations: p, significance level.
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3.2. Effects of Choline Supplementation on Lung Function and Liver Triglycerides
Forced Expiratory Volume in 1 second percent of predicted (ppFEV1) was improved after choline
supplementation (Figure 4), from 70.0 (50.9–74.8)% at V2 to 78.3 (60.1–83.9)% at V6, which is an
absolute improvement of 8.3 (3.6–9.2)% (p = 0.0137). At V5 (d49 (45–51)) there was no improvement
seen yet (69.9 [60.1–82.5]%). Similarly, forced vital capacity (FVC) and forced expiratory flow at 25–75%
of the pulmonary volume (FEF25-75) increased, with median improvements of 5.4 (−0.3–8.2)% and
7.6 (−0.8–8.4)%, respectively, at V6. Patient no. 5, whose ppFEV1 was 86.9% at V6 compared to 90.8%
at V2, apparently due to an airway infection, was included as a patient we intended to treat.
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fat was (Figure 5A) and the highest initial value (8.8%) from the patient with a F508del/Q552X 
mutation. This effect was specific to the liver, because there was no effect of choline supplementation 
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Figure 4. Effects of choline supplementation on lung function. Data indicate values prior to (V2)
and after 84 (84–91) days (V6) supplementation with 3 × 1 g/day choline chloride. Data indicate
age-corrected Relative Forced Expiratory Volume in 1 second (Tiffeneau Index; ppFEV1) (A), Forced
Vital Capacity (FVC) (B) and Forced Expiratory Flow at 25–75% of the pulmonary volume (FEF25-75)
(C). Small symbols and thin lines indicate individual values of patients, whereas large symbols and
thick bars indicate medians and interquartile ranges. p significance level.
Additionally, choline supplementation decreased liver fat from 1.6 (0.8–3.4)% (range: 0.4–8.8%)
to 0.8 (0.6–1.2)% (range: 0.4–2.1%) (p = 0.0039), with improvements the larger the higher initial liver
fat was (Figure 5A) and the highest initial value (8.8%) from the patient with a F508del/Q552X
mutation. This effect was specific to the liver, because there was no effect of choline supplementation
on muscle fat concentration (Figure 5B), whereas increased muscle choline and creatine, using activated
(betaine-derived) methyl groups for hepatic synthesis [14] were significantly increased (Figure 5C,D).
There was no significant difference between effects on CF patients homozygous for F508del and
compound heterozygous patients.
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Figure 5. Effects of choline supplementation on liver and muscle tissue. Liver (A) and muscle fat (B),
and muscle creatine (C) and choline (D) were investigated with magnetic resonance spectroscopy as
shown in Materials and Methods. Small symbols and thin lines indicate individual values of patients,
whereas large symbols and thick bars indicate medians and interquartile ranges. p, significance level.
3.3. Effects of Choline Supplementation on Plasma Phosphatidylcholine Metabolism
We further investigated whether choline supplementation increased plasma PC concentration
and influenced its metabolism in these patients. Endogenous plasma PC concentration prior to
choline supplementation was 1.00 (0.85–1.19) mmol/L, and was not altered after 49 (45–51) d or
84 (84–91) d choline supplementation (1.05 [0.96–1.23] and 1.01 [0.92–1.11] mmol/L, respectively).
Similarly, Figure 6A shows that the molecular composition of plasma PC was identical prior to
(white panels) and after (black panels) choline supplementation, with PC containing an oleic
(C18:1-PC), linoleic (C18:2-PC) or arachidonic (C20:4-PC) acid residue dominating over PC containing
docosahexaenoic acid (C22:6-PC).
At 33 h after [D9-methyl]choline administration, the plasma concentration of D9-PC
(primary outcome parameter) was 17.7 (15.5–22.4) µmol/L before, but only 12.2 (10.5–18.3) µmol/L
after choline supplementation (p < 0.05), reflecting higher D9-tracer dilution in response to choline
supplementation (see Discussion).
De novo PC synthesis, reflected by D9-PC [13,27], resulted in preferential synthesis of C18:1-D9-PC
and C18:2-D9-PC (Figure 6A, grey panels). By contrast, PC synthesis via the methylation of
phosphatidylethanolamine, resulting in D3-PC by using (D9-)betaine for the synthesis of D3-methionine
as a methyl donor [13,27] (Figure 6A, dotted panels), was preferential for the synthesis of PC containing
an arachidonic (C20:4-D3-PC) and docosahexaenoic acid residue (C22:6-D3-PC).
Although D9-choline enrichment of PC was decreased after choline supplementation, due to
refilled choline-containing precursor pools as outlined above, plasma kinetics were identical,
with maximum values at 24 h (Figure 6B). D3-enrichment of PC continuously increased, with identical
enrichment (Figure 6B) in spite of decreased deuterium enrichment of the D3-methyl donor D9-betaine
(Figure 3D). Finally, choline supplementation had no effect on the molecular specificity of PC synthesis
pathways (Figure 6C), indicating that choline supplementation had no effect on the homeostasis of
fatty acid or diglyceride precursors available for PC synthesis in these patients.
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Figure 6. Molecular composition and kinetics of plasma phosphatidylcholine (PC) in response to
choline supplementation. (A) PC molecular species grouped according to their content of different
fatty acid residues in sn-position 2 (Sat. PC, C18:1-PC, C18:2-PC, C20:4-PC or C22:6-PC). White panels
indicate the median PC composition prior to choline supplementation (visit [V] 2-4, whereas grey panels
are values after 84 d choline supplementation (V6-8). Striped panels indicate the molecular composition
of PC synthesized de novo (D9-PC), whereas dotted panels indicate synthesis via methylation of
phosphatidylethanolamine (D3-PC) [13,27]. (B) D9- and D3-enrichment of PC prior to and after choline
supplementation. (C) The relative synthesis rates and kinetics of plasma PC sub-groups are identical
prior to (visit [V] 2–4) and after (V6–8) 84 d choline supplementation. Data are medians and interquartile
ranges of N = 10. Abbreviations: ** p < 0.01; *** p < 0.001.
4. Discussion
Choline is essential to all cells, for membrane PC and SPM synthesis, methyl donation via
betaine to synthesize methionine from homocysteine for S-adenosylmethionine (SAM) regeneration,
and for other processes like osmoregulation [15]. SAM is required for hepatic PC synthesis via
phosphatidylethanolamine (PE) methylation, a pathway preferential for the synthesis of C20:4-PC and
C22:6-PC, and important to the assembly of very low density lipoproteins and triglyceride export from
the liver [13,27]. SAM/methionine/homocysteine imbalance was related to choline deficiency in CF
patients before [28]. However, the possible impact of choline deficiency on systemic PC metabolism,
and on the function of organs like the liver and lungs in CF, has only recently been described [13].
Choline metabolism is characterized by rapid plasma turnover, high turnover of liver PC via
the enterohepatic cycle of bile, and by pulmo ary PC secretion into the circulation via transfer to
apolipoprotein A1 [19,21–24,34]. In choli e deficiency, choline is drained from the lungs to meet
the requirements of the liver [25]. These physiological conditions impact on CF patients: exocrine
ancreatic insufficiency and low duodenal pH result in decreased pPLaseA2 activity, impairing the
cleavage of bile PC to lyso-PC and, therefore, the reabsorption and salvage of its choline moiety.
The resulting choline deficiency may impact on the liver, and pulmonary PC/choline drainage to feed
the liver may compromise epithelial integrity, repair and homeostasis of the chronically infla ed CF
lung [4,12,13]
The intention of this trial was to increase the low plasma concentration of choline and PC in CF
patients, as the cellular uptake and availability of choline for cellular PC synthesis is proportional to its
plasma concentration [13,35–37]. [D9-methyl]choline served to assess the supplementation effect on
plasma choline and hepatic PC secretion and kinetics [13,26,27]. Choline supplementation increased
plasma choline from ~5 mmol/L to normal values of 10–15 µmol/L, suggesting refilled choline
pools in CF patients. Whereas choline supplementation did not increase plasma PC concentration,
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it decreased D9-choline enrichment of PC and total D9-PC concentration after [D9-methyl]choline
intake. This suggests stronger dilution of the D9-tracer, and supports the concept of increased
tissue concentrations of PC precursors (choline, phosphocholine, CDP-choline [37]) in response to
supplementation. Hence, 3 × 1 g/day choline chloride, equaling 2.2 g choline, the 4-fold adequate
intake of healthy adult men [16], effectively ameliorated choline deficiency in CF patients. This is in
line with the improvement of the methionine/homocysteine status in response to a similar dosage of
choline in pediatric CF patients [28].
Although being secondary outcome parameters in this study, improved lung function and
decreased liver fat indicate the clinical relevance of correcting choline deficiency in CF patients.
Improved ppFEV1 after 84 d choline supplementation is consistent with previous data showing the
direct correlation of plasma choline and lung function in CF, and suggest a causal relationship rather
than an association [13].
The mechanisms involved, however, require further investigation, but may relate to the improved
choline availability of the lungs. In this organ, PC is exclusively synthesized de novo from exogenous
choline uptake, proportional to its extracellular concentration [15,35,36,38]. Beyond its functions
in membranes and surfactant, and its secretion into the circulation, via basolateral ATP-binding
cassette transporter A1 (ABC-A1), to feed systemic lipoprotein homeostasis and the liver in choline
deficiency [22–25], PC serves to remove pro-apoptotic ceramides via sphingomyelin (SPM) synthase
(EC2.7.8.27) [3]. In CF lungs, such ceramides are increased via SPM cleavage by acid sphingomyelinase
(ASM) (EC3.1.4.12), which causes poor lung function. Decreasing ceramide production by ASM
inhibition significantly reduces inflammation and epithelial apoptosis, and improves lung function [1,2].
Increasing the backward reaction of ceramide removal by SPM synthase requires sufficient amounts
of PC as a substrate. Correcting for the choline deficiency is a plausible mechanism to improve
lung function in these patients, which requires further investigation. A ferret or pig CFTR knockout
model, mimicking both the gastrointestinal and pulmonary pathology of human CF more closely than
mouse models [39,40], may be useful to further investigate the mechanisms involved. Experiments
will have to show whether impaired pancreas function results in choline deficiency as a general
mechanism impacting on lung and liver function in CF, and whether choline supplementation will
improve pulmonary choline, PC and ceramide homeostasis as well as chronic inflammation and loss
of organ function.
Choline supplementation diminished liver fat, too. PC synthesis via de novo synthesis and
methylation of phosphatidylethanolamine (PE) via PE-N-methyltransferase (PEMT) are essential for
hepatic triglyceride export [19]. Whereas, de novo synthesis directly uses choline, the PEMT pathway
uses S-adenosylmethionine (SAM), whose methyl groups can be derived from choline via betaine,
and results in D3- rather than D9-PC [13,27,41]. Both of these were measurable prior to and after
choline supplementation, suggesting the presence of both pathways in CF liver as shown before [13].
The decreased in liver triglycerides suggests that during choline supplementation increased liver
triglycerides were exported. Whereas plasma PC and triglycerides were not increased, concentrations
were measured after 49 d (V5) and 84 d (V6), when triglyceride export from liver was accomplished.
Such supplementation effects on triglycerides were specific for the liver, as triglycerides were not
changed in muscle tissue, whereas free choline and creatine, requiring SAM as a methyl donor for hepatic
synthesis [14], were increased in muscle tissue. These data further suggest a systemic improvement of the
choline status in these patients. Moreover, synthesis of D3-PC (see Figure 6B and [13,27]), which requires
(D3-)SAM, proves that D9-choline is used as a methyl donor for D3-SAM synthesis from homocysteine and
D9-betaine. Hence, choline supplementation not only increases its availability for PC synthesis but also for
methyl donation via betaine. By contrast, choline supplementation did not change the fatty acid pattern
in plasma PC, particularly not the fraction of C20:4-PC and C22:6-PC, their primarily transport vehicle in
plasma. Hence, choline supplementation does not impact on the potential DHA/ARA imbalance in CF
patients [13,42–44].
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Limitations
This is a pilot study on the metabolic and clinical impact of correcting for the choline deficiency
in CF patients with exocrine pancreatic insufficiency, by choline supplementation based on clinical and
experimental data, and on the application of pathophysiological considerations [1–3,13]. Whereas this
concept proved reasonable, choline turnover was very rapid so that plasma choline, betaine and TMAO
decreased to baseline concentrations within 60 h after the last choline dose (V6–V8). Hence, the rapid
choline turnover is limiting and may require an approach superior to choline chloride. Whether other
choline carriers, like glycerophosphorylcholine or PC, are superior to the plasma kinetics free choline
salts [45,46], will have to be addressed in humans. Moreover, this trial was not randomized or
placebo-controlled, and only blinded for the pre-post-analysis of the primary and biochemical outcome
parameters (plasma D9-PC etc.). There was no follow-up in this trial, which will have to be included
in future, and it was conducted on a rather homogenous and stable collective of adult patients
with ppFEV1 > 40% in males. The reasoning here was that PEMT gene expression, which reduces
exogenous choline requirements, is higher in pre-menopausal women compared to men, due to
its stimulation by estrogens. On the other hand, single nucleotide polymorphisms of this gene are
frequent, making female CF patients a more heterogenous collective [19,47,48]. Moreover, while PEMT
gene expression by high estrogen levels does not apply to children, their choline requirements are
higher due to growth requirements [15,16,18]. Finally, our study collective comprised CF patients
homozygous for F508del as well as F508del compound heterozygous patients with exocrine pancreas
insufficiency. In essence, our results serve as a proof of principle, but generalization of the effect
of choline supplementation in CF patients awaits further investigation in clinical trials addressing
the effects of choline supplementation in men, women, and children and with different CFTR
genotypes. Importantly, the structural and functional impairment of the exocrine pancreas occurs
rapidly after birth, suggesting that early intervention to improve choline homeostasis may be useful.
Routine finding of low plasma choline in pediatric patients of our outpatient CF clinic and others
before [49] support this view. While novel CFTR channel correctors significantly improve lung
function in CF patients, nothing is known about their effects on systemic choline homeostasis [50,51].
Hence, choline supplementation appears to be an option for CF treatment, complementary to other
innovative therapies.
5. Conclusions and Perspective
Choline supplementation normalizes the decreased concentration of plasma choline and of
PC precursors in the liver of CF patients with exocrine pancreas insufficiency. It improves lung
function and hepatosteatosis in these patients, complementary to standard care and, possibly,
other therapeutic innovations. The relevance of choline as an essential nutrient for parenchymal
growth and homeostasis suggests its supplementation in children [15]. The rapid return of plasma
choline to baseline concentration suggests further efforts to optimize the galenics of choline and to
assess the duration of clinical improvements in randomized trials.
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Appendix A
Table A1. Parameters of Phos CF-II patients.
Inclusion Parameters Exclusion Parameters
1. ≥18 years, male
2. Proven cystic fibrosis
3. Pancreas insufficiency
4. Plasma phosphatidylcholine below 2
mmol/L or hepatosteatosis or plasma
choline below 10 µmol/L
5. Written informed consent
1. Liver cirrhosis or congestion or
portal hypertension
2. Hyperreagibility against
choline-containing supplements
3. Allergic bronchopulmonary aspergillosis or
exacerbations of pulmonary infection requiring
systemic glucocorticoid treatment
4. ppFEV1% (Forced Expiratory Volume in 1 s
relative to Forced Vital Capacity) below 40% *
5. Nicotine abuse
6. Chronic alcohol abuse
7. Other diseases with potential impact on hepatic
lipid metabolism, like hypo-/hyperthyroidism,
renal diseases, significant left or right
ventricular dysfunction, dyslipidemia
8. Pacemaker, implants, piercings, non-removable
metal parts or other reasons like claustrophobia
precluding magnetic resonance spectroscopy
Ten patients were included after written consent. * one patient had 38% ppFEV1 at V1, but was included in the
intention to treat analysis.
Table A2. Primary and secondary end points of 90 d choline supplementation in adult CF patients.
Days (d) Relative to Start of Supplementation Visit 2–4(−2 to 0)
Visit 5
(d 49)
Visit 6–8
(d 84–86)
Primary Endpoint
Plasma D9-PC Concentration 33 h after D9-choline x x
Predefined Secondary Endpoints
Lung Function (FEV1, FVC, MEF-25, MEF 25-75) x x x
Liver Fat; Muscle Creatine, Choline, and Fat x x
Plasma Choline, Betaine, Dimethylglycine,
Methionine, Homocysteine, Trimethylamine Oxide
x x x
Plasma Phosphatidylcholine (PC), Sphingomyelin
(SPH), Phosphatidylethanolamine (PE)
x x x
Plasma Triglycerides, HDL-Cholesterol,
LDL-Cholesterol,
x x
Additional Secondary Outcome Parameters
Kinetics of D9-Choline, D9-Betaine, D9-PC, D3-PC;
Molecular Composition of Plasma PC
x
x
x
x
Abbreviations: D, deuterium; FEF25-75, forced expiratory flow at 25–75% of the pulmonary volume; FVC,
forced vital capacity; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PC, phosphatidylcholine;
PE, phosphatidylethanolamine; p.o., per os; ppFEV1, forced expiratory volume in one second percent of predicted;
SPM, sphingomyelin.
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Figure A1. Patient flow of choline supplementation pilot study in adult male CF patients. The protocol was
approved by The Institutional Review Board, and registered at ClinicalTrials.gov (Identifier: NCT 03312140).
Table A3. Anthropometric and laboratory parameters of patients.
Visit V1 V2–4 V5 V6–8
Days (d) relative to d −14 d -2 to 0 d 49 d 84 to 86
start of supplementation
Age (years) 24 (20–34); range 18–46
Choline Intake (days) – – 49 (45–51) V6: 84 (84–91)
Body Weight (kg) 65 (61–71) 63 (61–70) 62 (60–70)
Length (cm) 173 (171–175)
BMI (kg/m2) 22.7 (21.3–23.6) 21.6 (21.2–23.3) 21.7 (21.0–23.3)
Heart Rate (bpm) 72 (72–81) 77 (73–88) 78 (72–81) 78 (73–85)
Systolic BP (mmHg) 120 (112–125) 117 (73–88) 115 (114–124) 114 (110–119)
Diastolic BP (mmHg) 75 (65–75) 68 (66–76) 70 (67–76) 67 (65–73)
HbSO2 (%) 97 (95–97) 96 (95–97) 96 (96–97) 97 (95–98)
Sodium (mmol/L) 141 (139–141) 141 (140–142) 140 (137–142) 140 (139–141)
Potassium (mmol/L) 4.0 (3.9–4.4) 3.9 (3.7–4.2) 4.0 (3.9–4.4) 3.9 (3.7–4.1)
Creatinine (mmol/L) 0.9 (0.7–0.9) 0.8 (0.7–1.0) 0.9 (0.7–0.9) 0.8 (0.7–1.0)
Urea (mmol/L) 33 (26–36) 27 (25–33) 31 (26–37) 29 (23–34)
AST (U/L) 41 (27–74) 34 (27–50) 30 (25–41) 33 (23–37)
ALT (U/L) 48 (27–77) 35 (27–68) 36 (27–48) 34 (27–42)
GGT(U/L) 21 (14–64) 17 (16–56) 22 (17–69) 17 (14–22)
AP (U/L) 116 (103–138) 125 (102–163) 97 (95–134) 117 (105–121)
ilirubin (mg/dL) 0.70 (0.48–0.95) 0.65 (0.43–0.90) 0.60 (0.50–0.70) 0.75 (0.50–1.08)
Cholesterol (mg/dL) 124 (98–144) 132 (106–155) 142 (106–154) 125 (102–142)
HDL-Chol. (mg/dL) 35 (27–49) 41 (33–46) 38 (32–39) 40 (34–44)
LDL-Chol. (mg/dL) 58 (52–90) 64 (59–112) 61 (49–102) 68 (49–93)
Apo-B (mg/dL) 61 (50–71) 60 (52–79) 62 (49–85 62 (49–75)
Triglycerides (mg/dL) 65 (62–90) 64 (56–99) 84 (65–137) 87 (64–110)
Hemoglobin (g/dL) 15.5 (15.0–15.9) 14.7 (14.5–16.4) 15.0 (14.0–15.2) 14.7 (14.4–15.6)
Leucocytes (µL-1) 8170 (7103–9413) 8575 (7033–9610) 9040 (6840–9580) 8830 (7265–9890)
Thromboc. (x103/mL) 236 (193–262) 264 (240–281) 252 (222–300) 254 (210–288)
CRP (mg/dL) 0.35 (0.16–0.7) 0.33 (0.18–0.50) 0.17 (0.10–0.60) 0.70 (0.23–0.89)
Interleukin 6 (ng/L) 2.0 (2.0–7.0) 4.0 (2.5–6.1) 2.5 (2.0–4.9) 3.5 (2.5–6.4)
Data are medians and interquartile range of 10 patients at study entry (visit 1[V1]), start (V ), intermediate visit
(V5) and end of supplementation (V6). Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase;
Apo-B, apolipoprotein B; AST, aspartate aminotransferase; BP, blood pressure; Chol., cholesterol; CRP, C-reactive
protein; GGT, γ-glutamyl transferase; HbSO2, hemoglobin oxygenation; HDL, high-density lipoprotein; LDL,
low-density lipoprotein.
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